Cover Image
市場調查報告書

復發惡性神經膠母細胞瘤:開發平台分析

Recurrent Malignant Glioma - Pipeline Review, H2 2016

出版商 Global Markets Direct 商品編碼 247796
出版日期 內容資訊 英文 45 Pages
訂單完成後即時交付
價格
Back to Top
復發惡性神經膠母細胞瘤:開發平台分析 Recurrent Malignant Glioma - Pipeline Review, H2 2016
出版日期: 2016年12月30日 內容資訊: 英文 45 Pages
簡介

復發惡性神經膠母細胞瘤定義為治療後復發的腫瘤。治療方法包含化療和放射線治療等。

本報告提供復發惡性神經膠母細胞瘤的治療藥開發情形調查分析,提供您開發中產品概要,臨床實驗的各階段產品概要,主要企業簡介,藥物簡介,開發中產品的最新趨勢,最新消息和新聞稿等相關的系統性資訊。

目錄

簡介

復發惡性神經膠母細胞瘤概要

治療藥的開發

  • 開發中產品:概要
  • 開發中產品:比較分析

正在開發的治療藥:各企業

調查中的治療藥:大學/研究機關別

開發中產品的概要

  • 臨床實驗階段的產品

開發中的產品:各企業

調查中的產品:大學/研究機關別

開發治療藥的企業

  • Amgen Inc.
  • AstraZeneca Plc
  • Eisai
  • MediGene AG
  • Tiziana Life Sciences Plc
  • ZIOPHARM Oncology, Inc.

治療藥的評估

  • 單劑產品
  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介

  • Ad-RTS-IL-12
  • Carboxyamidotriazole Orotate
  • Cell Therapy for Refractory Gliomas
  • Cell Therapy to Target IL-13 for Malignant Glioma
  • Dendritic Cell Therapy for Oncology
  • Dendritic Cell Therapy for Recurrent Malignant Glioma
  • disufenton sodium
  • DNX-2401
  • G-207
  • irofulven
  • milciclib
  • rilotumumab

開發中產品的最新趨勢

暫停的計劃

開發中止的產品

產品開發的里程碑

  • 最新消息和新聞稿

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC8908IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Recurrent Malignant Glioma - Pipeline Review, H2 2016, provides an overview of the Recurrent Malignant Glioma (Oncology) pipeline landscape.

Recurrent malignant glioma is defined as recurrence of tumor after treatment. Symptoms include chest pain due to a tumor located in the chest area of the spinal cord, erectile dysfunction, lack of ability to feel changes in temperature, loss of muscle control, loss of bowel or bladder control, numbness or tingling, pain in the arm, neck, back, or leg caused by tumors in the neck area of the spinal cord and weakness in the limbs or upper body. Treatment includes chemotherapy and radiation therapy

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Recurrent Malignant Glioma - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Recurrent Malignant Glioma (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Recurrent Malignant Glioma (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Recurrent Malignant Glioma and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II and Phase I stages are 2 and 2 respectively. Similarly, the Universities portfolio in Phase II and Phase I stages comprises 3 and 2 molecules, respectively.

Recurrent Malignant Glioma (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Recurrent Malignant Glioma (Oncology).
  • The pipeline guide reviews pipeline therapeutics for Recurrent Malignant Glioma (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Recurrent Malignant Glioma (Oncology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Recurrent Malignant Glioma (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Recurrent Malignant Glioma (Oncology)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Recurrent Malignant Glioma (Oncology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Recurrent Malignant Glioma (Oncology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Recurrent Malignant Glioma Overview
  • Therapeutics Development
    • Pipeline Products for Recurrent Malignant Glioma - Overview
    • Pipeline Products for Recurrent Malignant Glioma - Comparative Analysis
  • Recurrent Malignant Glioma - Therapeutics under Development by Companies
  • Recurrent Malignant Glioma - Therapeutics under Investigation by Universities/Institutes
  • Recurrent Malignant Glioma - Pipeline Products Glance
    • Clinical Stage Products
  • Recurrent Malignant Glioma - Products under Development by Companies
  • Recurrent Malignant Glioma - Products under Investigation by Universities/Institutes
  • Recurrent Malignant Glioma - Companies Involved in Therapeutics Development
    • 2-BBB Medicines BV
    • AbbVie Inc
    • DNAtrix Inc
    • GtreeBNT Co Ltd
  • Recurrent Malignant Glioma - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • 2B3-101 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Cellular Immunotherapy for Oncology - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Cellular Immunotherapy for Recurrent Malignant Glioma - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Cellular Immunotherapy to Target EphA2 for Recurrent Malignant Glioma - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Cellular Immunotherapy to Target IL-13 for Malignant Glioma - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • depatuxizumab mafodotin - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • disufenton sodium - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • DNX-2401 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Vaccine to Target URLC10, DEPDC1, FOXM1, KIF20A VEGFR1 and VEGFR2 for Malignant Glioma - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Recurrent Malignant Glioma - Dormant Projects
  • Recurrent Malignant Glioma - Discontinued Products
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Recurrent Malignant Glioma, H2 2016
  • Number of Products under Development for Recurrent Malignant Glioma - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Products under Development by Companies, H2 2016
  • Products under Investigation by Universities/Institutes, H2 2016
  • Recurrent Malignant Glioma - Pipeline by 2-BBB Medicines BV, H2 2016
  • Recurrent Malignant Glioma - Pipeline by AbbVie Inc, H2 2016
  • Recurrent Malignant Glioma - Pipeline by DNAtrix Inc, H2 2016
  • Recurrent Malignant Glioma - Pipeline by GtreeBNT Co Ltd, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Stage and Target, H2 2016
  • Number of Products by Stage and Mechanism of Action, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • Recurrent Malignant Glioma - Dormant Projects, H2 2016
  • Recurrent Malignant Glioma - Discontinued Products, H2 2016

List of Figures

  • Number of Products under Development for Recurrent Malignant Glioma, H2 2016
  • Number of Products under Development for Recurrent Malignant Glioma - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Top 10 Targets, H2 2016
  • Number of Products by Stage and Top 10 Targets, H2 2016
  • Number of Products by Mechanism of Actions, H2 2016
  • Number of Products by Stage and Mechanism of Actions, H2 2016
  • Number of Products by Routes of Administration, H2 2016
  • Number of Products by Stage and Routes of Administration, H2 2016
  • Number of Products by Molecule Types, H2 2016
  • Number of Products by Stage and Molecule Types, H2 2016
Back to Top